HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.

Aims: Serous carcinoma is the prototype of type 2 uterine carcinoma. In many cases, establishing a diagnosis is straightforward, but problems can arise in that papillary variants of endometrioid carcinoma may be mistaken for serous carcinoma, and glandular variants of serous carcinoma may be misdiagnosed as endometrioid carcinoma. Markers such as p53, oestrogen receptor and p16 may be of use in problematic cases, but there is overlap and these may not therefore be of value in an individual case.

Misplaced Skene's glands: glandular elements in the lower female genital tract that are variably immunoreactive with prostate markers and that encompass vaginal tubulosquamous polyp and cervical ectopic prostatic tissue.

So-called ectopic prostatic tissue in the cervix and vaginal tubulosquamous polyps are rare morphologically similar lesions that may show positive immunohistochemical staining with prostatic markers. It has been suggested that they are related to paraurethral Skene's glands that are the female equivalent of prostatic glands in the male. We report a large series of lesions in women aged 23 to 81 years, found within the cervix (n=24), vagina (n=10), and vulva (n=2), which we believe to be a part of a spectrum of lesions derived from Skene's glands, either eutopic or more commonly misplaced during embryonic development.

A Strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia.

Numerous studies have investigated p53 immunohistochemistry as a diagnostic, prognostic or predictive marker in various neoplasms. However, the literature is confused and contradictory paying little attention to pivotal aspects of p53 biology nor basic immunohistochemical principles. Here we highlight the effect of varying antibody concentration on p53 immunohistochemical expression.